20 results about "Mucosal lesions" patented technology

The invention discloses a traditional Chinese medicine-probiotic combined preparation, a preparation method thereof and application of the traditional Chinese medicine-probiotic combined preparation in gastric mucosal lesion protection. The preparation is composed of a traditional Chinese medicine extract and a bacillus subtilis bacterial suspension, the traditional Chinese medicine extract is prepared from radix codonopsis, rhizoma smilacis glabrae, rhizoma atractylodis macrocephalae, fructus aurantii, radix aucklandiae, bletilla striata, herba ecliptae, radix salviae miltiorrhizae, fructus arctii and fructus psoraleae according to a specific proportion through water decoction, filtration, freeze-drying and mixing with the prepared bacterial suspension. The combined preparation has remarkable protection and treatment effects on gastric mucosal lesion caused by helicobacter pylori infection and ethanol, not only can effectively inhibit the growth of helicobacter pylori, but also can relieve gastric inflammatory response and apoptosis, and the effect of the combined preparation is equivalent to or even better than that of a conventional triple therapy or omeprazole. Meanwhile, the preparation shows synergistic interaction functions of regulating body immunity and maintaining intestinal flora balance, the preparation process is simple and convenient, the safety is high, and the preparation has wide application prospects in preparation of drugs for resisting helicobacter pylori, protecting gastric mucosa and regulating intestinal flora.

The first aspect of this invention provides a polarized illumination system for providing illumination light to biological tissue, comprising at least one laser, a lens, and a polarization-maintaining fiber. The second aspect provides a polarized imaging system for receiving light reflected or scattered by biological tissue after illumination, comprising an analyzer, an imaging lens, and a photosensitive device. The third aspect provides another polarized imaging system, comprising an imaging lens, a polarizing beam splitter, and a photosensitive device. The fourth aspect provides an endoscope system comprising the aforementioned polarized illumination system and polarized imaging system. This invention utilizes the different depolarization characteristics of scattered light at different depths to achieve separate imaging of specular reflection light, surface scattered light, and deep scattered light, greatly improving the visibility of mucosal surface and deep mucosal information, and significantly enhancing the visibility of various mucosal lesions.

The invention belongs to the technical field of biological medicines, and particularly relates to a multifunctional peptide and application thereof in anti-inflammatory, antibacterial, mucous membrane repair and intestinal secretion promotion. Specifically, the invention designs a polypeptide and an analogue which have guanylate cyclase C receptor (GUCY2C) agonist activity and anti-inflammatory, antibacterial and mucous membrane repair functions at the same time. The polypeptide can be combined with GUCY2C, stimulate generation of cyclic guanosine monophosphate (cGMP) in cells, promote intestinal fluid secretion, inhibit release of proinflammatory factors, relieve inflammatory response, promote repair of intestinal injury mucosa, inhibit growth of opportunistic pathogenic bacteria and accelerate intestinal homeostasis recovery after intestinal preparation. The composition can effectively promote intestinal tract cleaning, does not cause intestinal inflammation and mucosal lesion, has no hemolytic toxicity and cytotoxicity, is high in safety, and has a good clinical application prospect.

The invention belongs to the technical field of biological medicine, and discloses ovomucoprotein glycopeptide and application thereof. According to the application of the ovomucoprotein glycopeptide in preparing the medicine for preventing or treating the alcohol-induced acute gastric mucosal lesion, the percentage of the gastric mucosal lesion area can be reduced to 1.0% or below when the ovomucoprotein glycopeptide is used for protection. The invention creatively discovers and verifies that the glycopeptide derived from ovomucin has a remarkable protective effect on acute gastric mucosal lesion induced by alcohol. According to the discovery of the application, the application field of the natural active ingredient ovomucin is definitely expanded to the protection of acute gastric mucosal lesion for the first time, the technical problem that efficient and natural gastric mucosal protection ingredients are lacked in the prior art is solved, and a brand-new material basis and a clear direction are provided for developing a novel gastric mucosal protective agent.

The invention belongs to the technical field of medicines, and particularly relates to application of hibiscus (the hibiscus is a plant hibiscus flower and an extract and an active monomer thereof) in preparation of medicines for treating stomach diseases (atrophic gastritis, gastric mucosal lesion and gastric cancer). The invention discloses application of hibiscus syriacus in treatment of gastric diseases. The application comprises at least one of chronic atrophic gastritis treatment, gastric mucosa protection and gastric cancer prevention. In-vitro experiments show that the shrub althea flower extract, shrub althea flower polyphenol, syringic acid (I), protocatechuic acid (II), kaempferol (III) and kaempferol-7-O-beta-D-glucoside (IV) have obvious antioxidant activity and gastric mucosa protection activity, can obviously reduce the ROS content in ethanol-induced GES-1 cells and the expression of apoptosis marker protein Caspase-3 / Bax, and have a wide application prospect.

This utility model relates to the technical field of staining agent preparation equipment, and in particular to a staining agent preparation device for mucosal lesion diagnosis. It includes a placement cylinder and a top cover, and further includes: a disposable inner cylinder, which can slide inside the placement cylinder, and a quick-release positioning unit is provided between the disposable inner cylinder and the placement cylinder; a disposable rotating shaft, with several stirring rods fixed to its outer side, and a rotating unit is provided between the disposable rotating shaft and the top cover; and a liquid outlet pipe, with a B-hole on the lower side of the disposable inner cylinder, and the liquid outlet pipe is fixedly connected to the inner side of the B-hole, and can slide inside the positioning tube. By using a disposable inner cylinder, a disposable rotating shaft, and stirring rods, all of which are disposable items, they can be directly replaced after preparation without cleaning, thus avoiding residue and reducing the probability of cross-contamination, improving the production quality and efficiency of the reagent.

The invention relates to the technical field of probiotics, in particular to application of probiotics (in prevention and treatment of gastric mucosal lesion caused by non-steroidal anti-inflammatory drugs (NSAIDs)). The invention also relates to the application of the probiotics in the regulation of COX-1 and / or COX-2 in the stomach. The probiotics are Lactobacillus gasseri BKR-007, and the probiotics are Lactobacillus gasseri BKR-007. The strain BKR-007 can effectively antagonize damage of NSAIDs to gastric mucosa through a multi-mechanism synergistic effect, and the defense capability of the gastric mucosa is remarkably enhanced. The probiotics provide a novel and effective gastric mucosa protection choice for patients who need to take the medicines for a long time, and have a good clinical application prospect.

A method and device for multimodal imaging of dermal and mucosal lesions. The method includes using at least two imaging modalities from which one is a 3D scan of the lesion, and, additionally providing information on the distance and angulation between scanning device and the dermis or mucosa and mapping at least the second modality over the 3D data.

This invention relates to the application of Lactobacillus acidophilus CL-01 in the preparation of products for relieving pollen-induced allergic rhinitis; the CL-01 strain is Lactobacillus acidophilus with accession number GDMCC No:64731. Lactobacillus acidophilus CL-01 strain. This invention develops a new use for Lactobacillus acidophilus CL-01, providing a research basis for its widespread application. It also develops a novel strategy for alleviating pollen-induced allergic rhinitis. This invention finds that Lactobacillus acidophilus CL-01 has a very significant effect in alleviating symptoms related to pollen-induced allergic rhinitis, specifically by significantly improving symptoms such as nasal mucosal lesions, nasal itching, sneezing, runny nose, asthma, and intestinal flora imbalance caused by pollen-induced allergic rhinitis.

The invention belongs to the technical field of biological medicine, and particularly relates to PDRN, a preparation method and application of the PDRN in ulcerative colitis. The PDRN preparation method comprises the following steps: adding salmon sperms into a solvent, crushing to obtain a solid-liquid mixture, centrifuging, collecting precipitate, adding a mixed salt solution, and reacting to obtain a reaction solution; adding a compound enzyme into the reaction liquid, and performing enzymolysis to obtain enzymatic hydrolysate; and removing residual impurities after enzymolysis, carrying out alcohol precipitation, collecting the precipitate, washing the precipitate, centrifuging, collecting the precipitate, crushing the precipitate, and freeze-drying to obtain the PDRN. The PDRN provided by the invention has no cytotoxicity, and can significantly inhibit JAK / STAT and NF [kappa] B inflammation signal pathways and reduce the level of proinflammatory factors; the traditional Chinese medicine composition can improve weight loss, colon shortening, mucosal lesion and other symptoms caused by ulcerative colitis, reduce histological score and inflammatory cell infiltration, and play a synergistic treatment role by adjusting the diversity of intestinal flora.

The invention relates to the technical field of veterinary drugs, and particularly discloses a traditional Chinese medicine oral liquid preparation for treating diarrhea syndrome of newborn livestock and a preparation method thereof. The traditional Chinese medicine oral liquid preparation takes stenoloma chusanum, Chinese ilex leaves and liquorice as raw materials to prepare traditional Chinese medicine liquid, and then functional bacterial powder is added and mixed to prepare the oral liquid. According to the preparation, through the synergistic effect of traditional Chinese medicines and bacterial powder, core causes such as pathogenic bacterium infection, intestinal flora imbalance, mucosal lesion and low immunity of newborn livestock and poultry diarrhea are precisely targeted, rapid diarrhea checking is achieved, the cure rate is remarkably increased, and the recurrence rate is reduced; meanwhile, intestinal barriers are repaired, the body resistance is enhanced, nutrient absorption and post-disease growth are promoted, residues are avoided, drug resistance is avoided, the feed is adaptive to physiological characteristics of newborn livestock and poultry, and the resistance reducing requirement of green breeding is met.

The present invention relates to a topical composition comprising: a) 0.25% w / w to 1.5% w / w of hyaluronic acid or a salt thereof; b) from 0.01% w / w to 25% w / w of one or more adhesives; and c) from 0.005% w / w to 0.5% w / w of a non-absorbent antibiotic. The invention also relates to a delivery device comprising this composition and its use in medicine, in particular for the treatment and / or prevention of mucosal lesions; the traditional Chinese medicine composition is used for preventing polyp resection syndromes; the medicine is used as an adjuvant therapy for mechanical therapy in alimentary canal perforation; and as a sealant treatment for surgical anastomosis, leaks or fistula of the digestive tract.

The invention discloses a preparation method and application of elaeagnus angustifolia gum water-soluble homogeneous polysaccharide. According to the method, elaeagnus angustifolia gum is taken as a raw material, and the elaeagnus angustifolia gum water-soluble homogeneous polysaccharide is prepared through extraction, ethanol precipitation, separation and purification. Experiments show that the elaeagnus angustifolia gum water-soluble homogeneous polysaccharide reduces disease activity indexes and improves clinical symptoms by restoring body weight and excrement viscosity and reducing intestinal bleeding; the intestinal tract damaged by inflammation is relieved by repairing the mucosal barrier function of the colon tissue; by inhibiting mucosal lesion and remodeling an intestinal flora structure, dysbacteriosis induced by dextran sodium sulfate is reversed, and overall structure damage, mucosal lesion and colon tissue inflammation infiltration of DSS mice are effectively relieved. The application potential of the elaeagnus angustifolia gum water-soluble homogeneous polysaccharide in treatment of ulcerative colitis is disclosed, and the elaeagnus angustifolia gum water-soluble homogeneous polysaccharide is successfully endowed to the field of modern medicine from traditional application. Experimental research not only verifies the effectiveness of the compound, but also provides a new strategy and direct evidence for developing a novel and safe ulcerative colitis therapy derived from natural products, and has a clear application prospect.

This invention relates to the use of Streptococcus thermophilus CT-02 in the preparation of products for relieving pollen-induced allergic rhinitis; the CT-02 strain is Streptococcus thermophilus with accession number GDMCC No:64474. Streptococcus thermophilus CT-02 strain. This invention develops a new use for Streptococcus thermophilus CT-02, providing a research basis for its widespread application. It also develops a novel strategy for alleviating pollen-induced allergic rhinitis. This invention finds that Streptococcus thermophilus CT-02 has a very significant effect in alleviating symptoms related to pollen-induced allergic rhinitis, specifically by significantly improving symptoms such as nasal mucosal lesions, nasal itching, sneezing, runny nose, asthma, and intestinal flora imbalance caused by pollen-induced allergic rhinitis.

It relates to a topical composition comprising a) from 0.25 to 1.5% w / w of a hyaluronic acid or a salt thereof, b) from 0.01 to 25% w / w of one or more adhesive agents, and c) from 0.005 to 0.5% w / w of a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and / or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract.

The invention discloses an oral composition with a gastric mucosal lesion auxiliary protection function and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 3-10 parts of radix scutellariae, 3-10 parts of fermented soybean, 3-10 parts of fructus gardeniae, 3-10 parts of fructus aurantii immaturus, 3-10 parts of cortex magnoliae officinalis, 1-3 parts of radix glycyrrhizae preparata, 1-3 parts of rhizoma zingiberis, 1-3 parts of fructus jujubae, 3-10 parts of poria cocos, 2-10 parts of pericarpium citri reticulatae, 3-10 parts of herba patriniae, 3-10 parts of caulis bambusae in taeniam, 3-10 parts of flos inulae, 3-10 parts of ruddle, 1-5 parts of radix ginseng, 3-10 parts of rhizoma atractylodis macrocephalae, 3-10 parts of radix et rhizoma rhei preparata, 1-3 parts of radix notoginseng, 1-3 parts of According to the present invention, the scientific compatibility of the natural traditional Chinese medicine composition is adopted, the core pathological link of the gastric mucosa lesion is precisely focused, the multi-target synergistic effect of heat clearing, qi regulating, spleen strengthening, tissue regeneration promoting and the like is combined with the standardized extraction process to achieve the efficient and stable production, the composition is suitable for various dosage forms and applications, and the mild and strong-targeting conditioning scheme is provided for the protection and repair of the gastric mucosa.

The application belongs to the field of medicine and daily chemical industry, and particularly relates to a group of new polypeptides and application of the polypeptides in preparation of medicines for treating and / or preventing skin wound surface or mucous membrane damage. The new polypeptides can be combined with epidermal growth factor receptor EGFR to exert biological effects, and can be used for preparing medicines or daily chemical products for treating and / or preventing skin or mucous membrane diseases, acute and chronic gastrointestinal diseases, tumor and other related diseases.

The invention provides a novel guanidino cyclohexane derivative as shown in a formula I, a preparation method of the novel guanidino cyclohexane derivative and application of a pharmaceutical preparation containing the novel guanidino cyclohexane derivative in drugs for treating gastric mucosal lesions. The compound has a medicine development prospect for preventing and treating reflux esophagitis by adjusting the influence of nitric oxide synthase (NOS) and anti-inflammatory activity on microcirculation.

The invention provides a cobalt monatomic nano-enzyme system modified by polydopamine. The cobalt monatomic nano-enzyme system comprises cobalt monatomic nano-enzyme and a polydopamine coating layer coating the surface of the cobalt monatomic nano-enzyme, the cobalt monatomic nano enzyme is obtained by pyrolyzing and etching a precursor Co (at) MOF (at) SiO2. According to the invention, Co SA has activity similar to catalase and superoxide dismutase, and can accurately regulate and control oxidative stress and inflammatory reaction pathways induced by alcohol; the PDA realizes effective retention of Co SA in the stomach by virtue of biological adhesion, and the application safety is improved by virtue of good biocompatibility. The system can activate an NRF2 signal channel and inhibit an NF-kappa B signal channel to enhance the oxidation resistance of tissues and block an inflammatory cascade reaction, so that gastric mucosal lesion and hepatic lesion caused by alcohol are remarkably relieved, and oxidative stress and inflammatory reaction are improved. The invention provides a direction and an experimental basis for synchronous combined prevention and treatment of alcoholic gastritis and hepatitis.